COVID-19 (SARS-CoV-2) infection and thrombotic conditions: A systematic review and meta-analysis
- PMID: 33772772
- PMCID: PMC8250119
- DOI: 10.1111/eci.13559
COVID-19 (SARS-CoV-2) infection and thrombotic conditions: A systematic review and meta-analysis
Abstract
Background: COVID-19 is an infectious disease caused by SARS-CoV-2 associated with haematological manifestations (thrombolytic events).
Aims: Considering the high prevalence of the thrombotic scenarios associated with COVID-19, the aim of this study was to perform a systematic review of the available literature, concerning the relation of COVID-19 and the thrombotic events, and identify prognostic factors for these events.
Materials & methods: PubMed, Web of Science and Scopus databases were searched. Independent reviewers conducted all flow diagram steps. For qualitative analysis, Oxford level of evidence and Newcastle-Ottawa scale were used in the eligible articles. For the prognostic factors, a meta-analysis was conducted to age, number of neutrophils and platelets, and levels of ferritin, C-reactive protein, lactate dehydrogenase and D-dimer. Publication bias was accessed by funnel plot and by trim-and-fill test. Trim-and-fill test was also applied to evaluate meta-analysis bias.
Results: Twenty articles were included in the qualitative analysis, and 6 articles were included in the meta-analysis. Case-control studies showed bias related to exposure, and the main bias in cohort studies were related to selection and outcome. All articles received score 4 for the level of evidence. Hypertension and diabetes were the comorbidities more frequently associated with thrombolytic events. Significant results were found regarding D-dimer (P < .0001) and age (P = .0202) for thrombotic events in patients diagnosed with COVID-19.
Conclusion: Patients older than 60 years, with hypertension, diabetes and D-Dimer values above 3.17 µg/mL, can be considered prognostic factors for developing thrombotic events due to COVID-19.
Keywords: COVID-19; D-dimer; SARS-CoV-2; meta-analysis; prognostic factors; systematic review; thrombosis.
© 2021 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.
Conflict of interest statement
There is no conflict of interest involving any author in the present study.
Figures
References
-
- World Health Organization WHO . Director‐General's Statement on IHR Emergency Committee on Novel Coronavirus (2019‐nCoV) [Internet]. Genebra; 2020:1‐4. https://www.who.int/dg/speeches/detail/who‐director‐general‐s‐statement‐.... Accessed February 19, 2021.
-
- World Health Organization WHO . Clinical management of severe acute respiratory infection (SARI) when COVID‐19 disease is suspected. Interim guidance. Pediatria i Medycyna Rodzinna. 2020;16:9‐26.
Publication types
MeSH terms
Substances
Grants and funding
- 88887.468865/2019-00/Coordination for the Improvement of Higher Education Personnel (CAPES)
- 88887.571226/2020-00/Coordination for the Improvement of Higher Education Personnel (CAPES)
- 2018/18440-0/The São Paulo Research Foundation (FAPESP)
- 2020/07110-0/The São Paulo Research Foundation (FAPESP)
- 2019/08375-0/The São Paulo Research Foundation (FAPESP)
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
